tetano
Editor, Senior Moderator
Biochem Biophys Res Commun
. 2020 Nov 28;S0006-291X(20)32009-X.
doi: 10.1016/j.bbrc.2020.10.080. Online ahead of print.
The biogenesis of SARS-CoV-2 spike glycoprotein: multiple targets for host-directed antiviral therapy
Silvia Santopolo[SUP] 1 [/SUP], Anna Riccio[SUP] 1 [/SUP], M Gabriella Santoro[SUP] 2 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19 (coronavirus disease-19), represents a far more serious threat to public health than SARS and MERS coronaviruses, due to its ability to spread more efficiently than its predecessors. Currently, there is no worldwide-approved effective treatment for COVID-19, urging the scientific community to intense efforts to accelerate the discovery and development of prophylactic and therapeutic solutions against SARS-CoV-2 infection. In particular, effective antiviral drugs are urgently needed. With few exceptions, therapeutic approaches to combat viral infections have traditionally focused on targeting unique viral components or enzymes; however, it has now become evident that this strategy often fails due to the rapid emergence of drug-resistant viruses. Targeting host factors that are essential for the virus life cycle, but are dispensable for the host, has recently received increasing attention. The spike glycoprotein, a component of the viral envelope that decorates the virion surface as a distinctive crown ("corona") and is essential for SARS-CoV-2 entry into host cells, represents a key target for developing therapeutics capable of blocking virus invasion. This review highlights aspects of the SARS-CoV-2 spike biogenesis that may be amenable to host-directed antiviral targeting.
Keywords: Antiviral; COVID-19; Coronavirus; ERp57; Furin; N-Glycosylation.
. 2020 Nov 28;S0006-291X(20)32009-X.
doi: 10.1016/j.bbrc.2020.10.080. Online ahead of print.
The biogenesis of SARS-CoV-2 spike glycoprotein: multiple targets for host-directed antiviral therapy
Silvia Santopolo[SUP] 1 [/SUP], Anna Riccio[SUP] 1 [/SUP], M Gabriella Santoro[SUP] 2 [/SUP]
Affiliations
- PMID: 33303190
- PMCID: PMC7698684
- DOI: 10.1016/j.bbrc.2020.10.080
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19 (coronavirus disease-19), represents a far more serious threat to public health than SARS and MERS coronaviruses, due to its ability to spread more efficiently than its predecessors. Currently, there is no worldwide-approved effective treatment for COVID-19, urging the scientific community to intense efforts to accelerate the discovery and development of prophylactic and therapeutic solutions against SARS-CoV-2 infection. In particular, effective antiviral drugs are urgently needed. With few exceptions, therapeutic approaches to combat viral infections have traditionally focused on targeting unique viral components or enzymes; however, it has now become evident that this strategy often fails due to the rapid emergence of drug-resistant viruses. Targeting host factors that are essential for the virus life cycle, but are dispensable for the host, has recently received increasing attention. The spike glycoprotein, a component of the viral envelope that decorates the virion surface as a distinctive crown ("corona") and is essential for SARS-CoV-2 entry into host cells, represents a key target for developing therapeutics capable of blocking virus invasion. This review highlights aspects of the SARS-CoV-2 spike biogenesis that may be amenable to host-directed antiviral targeting.
Keywords: Antiviral; COVID-19; Coronavirus; ERp57; Furin; N-Glycosylation.